NRx Pharma

01/12/2026

People with bipolar disorder experience periods of unusually intense emotion, changes in sleep patterns and activity levels, and unusual behaviors. -National Institute of Mental Health

Learn about the basic types of bipolar disorder: https://go.nih.gov/EaCNJnr

$NRXP

Learn about NIMH research on bipolar disorder. Find resources on the signs and symptoms of bipolar disorder, types, and potential treatments and therapies.

01/09/2026

$NRXP

Learn More - https://www.nrxpharma.com/nrx-100-nrx-101/ -101

01/07/2026

New analyst report from D. Boral Capital - NRx and Neurocare Partner to Build a Nationwide Network

Read Report - https://ir.nrxpharma.com/analyst-coverage

$NRXP

01/06/2026

NRx Pharmaceuticals and neurocare Group AG Launch Joint Neuroplastic Therapy Offering

(Nasdaq: NRXP) and neurocare Group AG announced a joint offering of neuroplastic therapy aimed at treating depression, PTSD, and other mental health conditions, highlighting a collaborative approach to advancing mental health care.

READ HERE⬇️⬇️⬇️
https://bit.ly/NRXpressrelease

Check out the latest NewsOut update here⬇️⬇️⬇️
https://bit.ly/NTTS-NEWSOUT-NRXPharmaandNeurocareLaunchNeuroplasticTherapyforDepressionandPTSD

Watch the newest interview here⬇️⬇️⬇️
https://bit.ly/NTTS-RxPharmaAdvancesPTSDandDepressionTreatment

👉🏻Learn more at https://bit.ly/NRXPharmaceuticals

01/05/2026

NRx Pharmaceuticals (Nasdaq:NRXP) and neurocare Group AG Announce Joint Offering of Neuroplastic Therapy Targeting Depression, PTSD, and other mental health afflictions

Read More - https://ir.nrxpharma.com/news-releases/news-release-details/nrx-pharmaceuticals-nasdaqnrxp-and-neurocare-group-ag-announce

$NRXP

12/31/2025

NRX Pharmaceuticals Advances Mental Health Innovation

is dedicated to helping individuals with bipolar disorder, PTSD, and other psychiatric conditions return to full, productive lives, focusing its pipeline on NMDA receptor–modulated therapies.

Watch the newest New to The Street interview here⬇️⬇️⬇️
https://bit.ly/NTTS-RxPharmaAdvancesPTSDandDepressionTreatment

👉🏻Learn more at https://bit.ly/NRXPharmaceuticals

12/29/2025

NRx Pharmaceuticals is focused on the high unmet need for lifesaving treatments for people with severe bipolar depression and PTSD in the presence of suicidality.

Follow our journey.
NRxPharma.com

$NRXP

NRx creates innovative, life-saving treatments to address unmet medical needs and bring hope to those with chronic conditions. Learn More.

12/23/2025

From the NRx Pharmaceuticals family to yours, we wish you a Happy Holiday Season.

12/22/2025

NRx Pharmaceuticals (Nasdaq: NRXP) Eliminates All Balance Sheet Debt

announced the elimination of all balance sheet debt following a strategic equity conversion, strengthening the company’s financial position and flexibility for future growth.

This milestone highlights NRx’s commitment to capital efficiency, strategic restructuring, and shareholder value creation.

READ HERE⬇️⬇️⬇️
https://bit.ly/NRXpressrelease

Watch the newest New to The Street interview here⬇️⬇️⬇️
https://bit.ly/NTTS-RxPharmaAdvancesPTSDandDepressionTreatment

👉🏻Learn more at https://bit.ly/NRXPharmaceuticals

12/19/2025

$NRXP

Learn More - https://www.nrxpharma.com/nrx-100-nrx-101/ -101

12/18/2025

NRx Pharmaceuticals (Nasdaq:NRXP) announces elimination of all balance sheet debt following equity conversion

Read More - https://ir.nrxpharma.com/news-releases/news-release-details/nrx-pharmaceuticals-nasdaqnrxp-announces-elimination-all-balance

$NRXP

12/17/2025

New analyst report from H.C. Wainright & Co. - KETAFREE ANDA Acceptance Paves Clear Path to 2026 Revenue; Reiterate Buy

Read Report - https://ir.nrxpharma.com/analyst-coverage

$NRXP